EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Injectable hydrogels for personalized cancer immunotherapies

Neda Mohaghegh, Amir Ahari, Fatemeh Zehtabi, Claire Buttles, Saya Davani, Hanna Hoang, Kaylee Tseng, Benjamin Zamanian, Safoora Khosravi, Ariella Daniali, Negar Hosseinzadeh Kouchehbaghi, Isabel Thomas und 9 weitere

Acta Biomaterialia · 2023-12 · 172 · 67-91

DOI: 10.1016/j.actbio.2023.10.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Biomaterialia, 2023-12. Verfasst von Neda Mohaghegh und 20 weiteren Autor:innen. Beteiligte Einrichtung: Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA. Hauptthemen laut MEDLINE: Hydrogels, Neoplasms. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 210 Literaturangaben. Gefördert von: NIAMS NIH HHS, NCATS NIH HHS, Terasaki Institute for Biomedical Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The field of cancer immunotherapy has shown significant growth, and researchers are now focusing on effective strategies to enhance and prolong local immunomodulation. Injectable hydrogels (IHs) have emerged as versatile platforms for encapsulating and controlling the release of small molecules and cells, drawing significant attention for their potential to enhance antitumor immune responses while inhibiting metastasis and recurrence. IHs delivering natural killer (NK) cells, T cells, and antigen-presenting cells (APCs) offer a viable method for treating cancer. Indeed, it can bypass the extracellular matrix and gradually release small molecules or cells into the tumor microenvironment, thereby boosting immune responses against cancer cells. This review provides an overview of the recent advancements in cancer immunotherapy using IHs for delivering NK cells, T cells, APCs, chemoimmunotherapy, radio-immunotherapy, and photothermal-immunotherapy. First, we introduce IHs as a delivery matrix, then summarize their applications for the local delivery of small molecules and immune cells to elicit robust anticancer immune responses. Additionally, we discuss recent progress in IHs systems used for local combination therapy, including chemoimmunotherapy, radio-immunotherapy, photothermal-immunotherapy, photodynamic-immunotherapy, and gene-immunotherapy. By comprehensively examining the utilization of IHs in cancer immunotherapy, this review aims to highlight the potential of IHs as effective carriers for immunotherapy delivery, facilitating the development of innovative strategies for cancer treatment. In addition, we demonstrate that using hydrogel-based platforms for the targeted delivery of immune cells, such as NK cells, T cells, and dendritic cells (DCs), has remarkable potential in cancer therapy. These innovative approaches have yielded substantial reductions in tumor growth, showcasing the ability of hydrogels to enhance the efficacy of immune-based treatments. STATEMENT OF SIGNIFICANCE: As cancer immunotherapy continues to expand, the mode of therapeutic agent delivery becomes increasingly critical. This review spotlights the forward-looking progress of IHs, emphasizing their potential to revolutionize localized immunotherapy delivery. By efficiently encapsulating and controlling the release of essential immune components such as T cells, NK cells, APCs, and various therapeutic agents, IHs offer a pioneering pathway to amplify immune reactions, moderate metastasis, and reduce recurrence. Their adaptability further shines when considering their role in emerging combination therapies, including chemoimmunotherapy, radio-immunotherapy, and photothermal-immunotherapy. Understanding IHs' significance in cancer therapy is essential, suggesting a shift in cancer treatment dynamics and heralding a novel period of focused, enduring, and powerful therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrogelsNeoplasmsHumansImmunotherapyT-LymphocytesCombined Modality TherapyTumor Microenvironment

Stichwörter der Autor:innen

Adoptive cellular immunotherapyCancer immunotherapyImmune cell deliveryInjectable hydrogels

Substanzen

Hydrogels

Autor:innen und Institutionen

  • Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA.
  • Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Department of Surgery, University of California-Los Angeles, Los Angeles, CA 90095, USA.
  • Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Indiana University Bloomington, Department of Biology, Bloomington, IN 47405, USA.
  • Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90024, USA.
  • Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, California 90007, USA.
  • Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90064 USA; Department of Electrical and Computer Engineering, University of British Columbia, Vancouver, BC, V6T1Z4, Canada.

Förderung

  • NIAMS NIH HHS
  • NCATS NIH HHS
  • Terasaki Institute for Biomedical Innovation
  • National Institutes of Health
  • Foundation for the National Institutes of Health

Zitieren

APA

Mohaghegh, N., Ahari, A., Zehtabi, F., Buttles, C., Davani, S., Hoang, H., Tseng, K., Zamanian, B., Khosravi, S., Daniali, A., Kouchehbaghi, N. H., Thomas, I., Serati Nouri, H., Khorsandi, D., Abbasgholizadeh, R., Akbari, M., Patil, R., Kang, H., Jucaud, V., …, & Hassani Najafabadi, A. (2023). Injectable hydrogels for personalized cancer immunotherapies. Acta Biomaterialia, 172, 67-91. https://doi.org/10.1016/j.actbio.2023.10.002

Vancouver

Mohaghegh N, Ahari A, Zehtabi F, Buttles C, Davani S, Hoang H, et al. Injectable hydrogels for personalized cancer immunotherapies. Acta Biomaterialia. 2023;172:67-91. doi:10.1016/j.actbio.2023.10.002

BibTeX
@article{Mohaghegh2023,
  author = {Mohaghegh, Neda and Ahari, Amir and Zehtabi, Fatemeh and Buttles, Claire and Davani, Saya and Hoang, Hanna and Tseng, Kaylee and Zamanian, Benjamin and Khosravi, Safoora and Daniali, Ariella and Kouchehbaghi, Negar Hosseinzadeh and Thomas, Isabel and Serati Nouri, Hamed and Khorsandi, Danial and Abbasgholizadeh, Reza and Akbari, Mohsen and Patil, Rameshwar and Kang, Heemin and Jucaud, Vadim and Khademhosseini, Ali and Hassani Najafabadi, Alireza},
  title = {Injectable hydrogels for personalized cancer immunotherapies},
  journal = {Acta Biomaterialia},
  year = {2023},
  volume = {172},
  pages = {67--91},
  doi = {10.1016/j.actbio.2023.10.002}
}
Kostenlos starten →